10-Q: Celcuity Q1 Loss Widens Amid R&D Surge, Gedatolisib Progress

Celcuity Inc. reported a widened net loss in Q1 2026 due to increased R&D and commercialization expenses, while advancing its lead drug candidate gedatolisib with positive clinical trial results and an FDA Priority Review.

Summary

• Net loss for the three months ended March 31, 2026, widened to $52.8 million, compared to $37.0 million for the same period in 2025.
• Research and development expenses increased by 11% to $33.1 million in Q1 2026, primarily due to higher employee-related and consulting expenses, and manufacturing costs.
• Selling, general and administrative expenses surged by 174% to $17.4 million in Q1 2026, driven by commercial headcount additions and launch-related activities for gedatolisib.
• As of March 31, 2026, the company had $387.1 million in cash, cash equivalents, and short-term investments, with an accumulated deficit of $501.7 million.
• The FDA accepted the New Drug Application (NDA) for gedatolisib in HR+/HER2PIK3CA WT advanced or metastatic breast cancer (ABC), granting Priority Review with a PDUFA goal date of July 17, 2026.
• Positive topline results were announced on May 1, 2026, for the VIKTORIA-1 Phase 3 clinical trial's PIK3CA MT cohort, demonstrating statistically significant and clinically meaningful improvement in progression-free survival (PFS).
• The VIKTORIA-2 Phase 3 clinical trial's design was amended to include endocrine-sensitive patients and remove ribociclib as a treatment partner in one arm, with topline data expected by the end of 2028 for Study 1 and in 2030 for Study 2.
• An ongoing Phase 1b/2 clinical trial (CELC-G-201) for gedatolisib in metastatic castration-resistant prostate cancer (mCRPC) showed a 6-month radiographic PFS rate of 67% and median rPFS of 9.1 months for combined arms.
• A patent application was submitted to the USPTO for a subcutaneous formulation of gedatolisib, aiming to provide an alternative to intravenous administration.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as moderately positive due to significant clinical progress and regulatory milestones for gedatolisib, particularly the FDA Priority Review and positive topline data for the PIK3CA MT cohort. However, the widening net loss and increased operating expenses, while expected for a clinical-stage company nearing commercialization, highlight continued cash burn and the need for future capital.

Positives

• The FDA accepted the NDA for gedatolisib in HR+/HER2PIK3CA WT ABC, granting Priority Review with a PDUFA goal date of July 17, 2026, indicating potential market entry in H2 2026.
• Positive topline results from the VIKTORIA-1 Phase 3 clinical trial's PIK3CA MT cohort demonstrated statistically significant and clinically meaningful improvement in PFS, expanding gedatolisib's potential market.
• The VIKTORIA-1 (PIK3CA WT cohort) results were published in the Journal of Clinical Oncology, lending scientific credibility and visibility to the drug's efficacy.
• Gedatolisib triplet and doublet regimens in the VIKTORIA-1 (WT cohort) showed more favorable hazard ratios and higher incremental PFS improvements (7.3 and 5.4 months, respectively) than previously reported in Phase 3 trials for HR+/HER2ABC patients receiving at least second-line therapy.
• Gedatolisib is the first inhibitor targeting the PI3K/AKT/mTOR (PAM) pathway to demonstrate positive Phase 3 results in patients with HR+/HER2PIK3CA WT ABC whose disease progressed on or after treatment with a CDK4/6 inhibitor.
• The median duration of response (DOR) and incremental objective response rate (ORR) improvement for the gedatolisib triplet and doublet are the highest reported for an endocrine therapy-based regimen in second-line HR+/HER2ABC.
• The submission of a patent application for a subcutaneous gedatolisib formulation could offer a more convenient administration method, potentially improving patient compliance and market adoption.
• The company believes its existing cash, cash equivalents, and short-term investments will be sufficient to fund planned operations for at least one year from the issuance of the financial statements (through May 2027).
• No dose-limiting toxicities were observed in the CELC-G-201 Phase 1b trial for mCRPC, and the drug was generally well tolerated with mostly low-grade treatment-related adverse events.

Negatives

• Net loss significantly widened to $52.8 million in Q1 2026 from $37.0 million in Q1 2025, indicating increased cash burn.
• Selling, general and administrative expenses increased by 174% to $17.4 million, reflecting substantial investment in commercialization activities ahead of potential product launch.
• Interest expense rose by 91% to $6.1 million, primarily due to the issuance of convertible notes and additional loan disbursements.
• The accumulated deficit reached $501.7 million as of March 31, 2026, highlighting the company's history of operating losses.
• Cash and cash equivalents decreased by $20.5 million during the quarter, and total current assets decreased from $465.7 million to $408.9 million.

Risks

• Potential inability to develop, validate, obtain regulatory approval for, and commercialize gedatolisib on a timely basis or at all.
• Uncertainties and costs associated with clinical studies and with developing and commercializing pharmaceuticals.
• The complexity and difficulty of demonstrating the safety and sufficient magnitude of benefit to support regulatory approval of gedatolisib and other products that may be developed.
• Challenges in developing and maintaining relationships with pharmaceutical company partners, including current and any future suppliers of the product candidate.
• Maintaining continuity of clinical and commercial supply of gedatolisib.
• Uncertainty regarding market acceptance by physicians, patients, third-party payors, and others in the medical community, and with the size of market opportunities available.
• Difficulties in managing growth, such as hiring and retaining a qualified sales force and attracting and retaining key personnel.
• Changes in government regulations.
• Tightening credit markets and limitations on access to capital.
• Stock market volatility or other factors that may affect the ability to access capital on favorable terms or at all.
• Obtaining and maintaining intellectual property protection for gedatolisib, including its formulations and methods of use, and time and expense associated with enforcing intellectual property rights against third parties, and defending third-party claims of intellectual property infringement, investigations or litigation threatened or initiated.
• The company has not generated any revenue from product sales or other sources since inception and has incurred operating losses and negative cash flows from operations.
• The need for substantial additional financing to achieve its goals.
• Uncertainty of broad adoption of its approved products, if any, by physicians and consumers.
• Significant competition in the biotechnology and oncology sectors.

Future Outlook

The company expects to generate revenue from sales of gedatolisib commencing in the second half of 2026, contingent upon FDA approval. Research and development expenses are projected to increase for the foreseeable future as the company continues to develop gedatolisib and conduct ongoing clinical trials (VIKTORIA-2, CELC-G-201), along with follow-up activities for VIKTORIA-1. Selling, general and administrative expenses are also anticipated to rise due to planned commercialization efforts, expanding infrastructure, and public company regulatory requirements. Management believes current cash, cash equivalents, and short-term investments, combined with available borrowings, will fund operations through 2027. The company may seek additional capital through equity, convertible debt, or other funding arrangements. Topline data for VIKTORIA-2 Study 1 is expected by the end of 2028, and for Study 2 in 2030. The company intends to submit VIKTORIA-1 PIK3CA MT data to the FDA as a supplemental New Drug Application (sNDA) and to other regulatory authorities outside the U.S. following the sNDA submission. Development of a subcutaneous gedatolisib formulation is ongoing, aiming for clinical equivalence to the intravenous formulation.

Management Comments

• "We believe gedatolisibs unique mechanism of action, differentiated chemical structure, favorable pharmacokinetic properties, and intravenous route of administration offer distinct advantages over currently approved and investigational therapies that target PI3K, AKT, or mTORC1 alone or together."
• "With these results, the gedatolisib regimens represent a new potential standard of care for patients with HR+/HER2PIK3CA WT ABC whose disease progressed on or after treatment with a CDK4/6 inhibitor."
• "Based on our current business plan, we believe that our current cash, cash equivalents and short-term investments, together with available borrowings under the Amended A&R Loan Agreement, will provide sufficient cash to finance our operations through 2027."

Industry Context

StockSavvy.ai notes that Celcuity's significant clinical progress and regulatory milestones for gedatolisib, particularly the FDA Priority Review for the PIK3CA WT cohort and positive topline data for the PIK3CA MT cohort, position the company as a notable contender in the advanced breast cancer treatment landscape. Gedatolisib's differentiated mechanism of action, which comprehensively inhibits the PAM pathway, coupled with a potentially more tolerable intravenous administration profile compared to oral inhibitors, could address critical unmet needs in patients who have progressed on prior CDK4/6 therapy. This strategy aims to challenge existing therapies like alpelisib (a PI3K inhibitor) and capivasertib (an AKT inhibitor) by offering a broader and potentially better-tolerated treatment option. The ongoing trials in first-line ABC and mCRPC further indicate a strategic intent to expand gedatolisib's market potential beyond its initial indications, suggesting a long-term vision for the drug's role in oncology.

Comparison to Industry Standards

• The gedatolisib triplet (gedatolisib, fulvestrant, and palbociclib) demonstrated a 7.3-month incremental improvement in median PFS over fulvestrant (9.3 months vs. 2.0 months) in PIK3CA WT HR+/HER2ABC patients, which is higher than previously reported by any Phase 3 trial for this patient population receiving at least second-line therapy.
• The hazard ratios for the gedatolisib triplet (HR=0.24) and doublet (HR=0.33) are more favorable than previously reported by any Phase 3 trial for patients with HR+/HER2ABC.
• Gedatolisib is the first inhibitor targeting the PAM pathway to demonstrate positive Phase 3 results in patients with HR+/HER2PIK3CA WT ABC whose disease progressed on or after treatment with a CDK4/6 inhibitor, differentiating it from other PI3K, AKT, or mTORC1 inhibitors.
• The median DOR (17.5 months for the triplet, 12.0 months for the doublet) and incremental ORR improvement (31% for the triplet, 28.3% for the doublet vs. 1% for fulvestrant) are the highest reported for an endocrine therapy-based regimen in second-line HR+/HER2ABC.
• In the Phase 1b trial, gedatolisib showed Grade 3 or 4 hyperglycemia in 7% of patients and less than 9% discontinued treatment, which compares favorably to the FDA-approved oral p110-specific inhibitor PIQRAY, which induced Grade 3 or 4 hyperglycemia in 39% of patients and led to 26% discontinuing alpelisib due to treatment-related adverse events.

Corporate Governance

Legal Proceedings

• The company is not currently a party to any legal proceedings that could reasonably be expected to have a material adverse effect on its business, financial condition, and results of operations.

Related Party Transactions

• On May 1, 2026, Innovatus converted $3,438,029 of the outstanding principal of the Term A Loan into 343,802 shares of the company's common stock.

Stakeholder Impact

• **Shareholders**: Potential for significant value creation from successful FDA approval and commercialization of gedatolisib, especially given the Priority Review. However, continued widening losses and potential future capital raises could lead to dilution.
• **Employees**: Benefit from enhanced equity compensation opportunities through the new 2026 Stock Incentive Plan and the expanded 2017 Employee Stock Purchase Plan, which can aid in retention and motivation.
• **Customers (future patients)**: The positive clinical trial results and FDA Priority Review for gedatolisib offer the prospect of a new, potentially more effective and better-tolerated treatment option for patients with HR+/HER2ABC and mCRPC.
• **Creditors**: The company's debt obligations (convertible notes and loan agreements) are senior, and the company reports full compliance with all financial covenants as of March 31, 2026. Future draws on the loan facility are contingent on milestones.

Next Steps

• Detailed results from VIKTORIA-1 Study 2 (PIK3CA MT cohort) will be presented at the ASCO Annual Meeting on June 2, 2026.
• The PDUFA goal date for FDA approval of gedatolisib in HR+/HER2PIK3CA WT ABC is July 17, 2026.
• The company intends to submit VIKTORIA-1 PIK3CA MT data to the FDA as a supplemental New Drug Application (sNDA) and to other regulatory authorities outside the U.S. following the sNDA submission.
• Continue to develop gedatolisib, conduct the VIKTORIA-2 Phase 3 and CELC-G-201 Phase 1b/2 clinical trials, and continue follow-up activities for the VIKTORIA-1 Phase 3 clinical trial.
• Development of a subcutaneous gedatolisib formulation is ongoing with the goal of demonstrating clinical equivalence to the current intravenous formulation.
• Topline data for VIKTORIA-2 Study 1 is expected by the end of 2028.
• Topline data for VIKTORIA-2 Study 2 is expected in 2030.
• The company may seek to raise additional capital to finance capital expenditures and operating expenses over the next several years.

Key Dates

Recommendation

While Celcuity has achieved significant clinical and regulatory milestones for gedatolisib, including FDA Priority Review and positive Phase 3 results, the company continues to incur substantial operating losses and cash burn. The stock has likely priced in much of the recent positive news. A 'hold' recommendation is prudent, awaiting the PDUFA decision and further clarity on commercialization strategy and financial sustainability before a stronger stance can be taken.

Keywords

Celcuity, gedatolisib, biotechnology, clinical-stage, oncology, breast cancer, prostate cancer, PI3K/AKT/mTOR, VIKTORIA-1, VIKTORIA-2, CELC-G-201, FDA approval, NDA, Priority Review, PIK3CA, HR+/HER2ABC, mCRPC, clinical trials, pharmaceuticals, drug development